Manufacturing Updates in Brief
This article was originally published in The Gold Sheet
GMP issues delayed Boehringer launch; Nigerian firms meet WHO GMPs; Novartis closing Puerto Rico plant; Hospira closing Clayton site; Valeant looks to move Bausch + Lomb manufacturing abroad; these IV bags were training aides.
You may also be interested in...
A timeline chronicling the development of Boehringer Ingelheim’s chronic obstructive pulmonary disease treatment olodaterol.
Sponsor’s claimed impact on exercise tolerance was not adequately supported and should not serve as a marketing advantage for the chronic obstructive pulmonary disease drug, FDA review staff said. However, Boehringer Ingelheim’s failed attempt for the exercise-related labeling language spurred the agency to clarify the types of studies and endpoints that potentially could support such claims.
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.